What is Telomir Pharmaceuticals, Inc. (TELO) stock price today?

Telomir Pharmaceuticals, Inc. (TELO) is currently trading at $1.12, down 2.61% today.

What is TELO P/E ratio?

Telomir Pharmaceuticals, Inc.'s P/E ratio is -0.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is TELO return on equity (ROE)?

Telomir Pharmaceuticals, Inc.'s return on equity (ROE) is -102.69%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Telomir Pharmaceuticals, Inc.'s market cap?

Telomir Pharmaceuticals, Inc. has a market capitalization of $77.03M.

NASDAQ · Biotechnology

Telomir Pharmaceuticals, Inc. (TELO) Stock

$1.12 -2.61% NASDAQ: TELO Healthcare

Valuation

Metric	Value
Price	$1.12
Market Cap	$77.03M
P/E Ratio	-0.78
P/B Ratio	8.06
P/S Ratio	0.00
EPS (TTM)	$-0.33
52-Week High	$2.09
52-Week Low	$0.89
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-102.69%
ROA	-109.51%
ROCE	-120.93%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	7.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$0	$-1.0M	$-4.0M	$-12.0M	$-11.0M
Net Profit	$0	$-1.0M	$-13.0M	$-17.0M	$-10.0M
EPS	$0.00	$-0.03	$-0.44	$-0.56	$-0.33
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$0	$0	$5.0M	$1.0M	$7.0M
Total Liabilities	$0	$1.0M	$1.0M	$1.0M	$1.0M
Cash	$0	$0	$0	$1.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model ACCESS Newswire · Jun 15, 2026 Telomir Names Andriy Mushak as Fractional Chief Financial Officer MT Newswires · Jun 9, 2026 Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease ACCESS Newswire · May 20, 2026 Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer MT Newswires · Apr 30, 2026 Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer ACCESS Newswire · Apr 30, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$0	$0	$-4.0M	$-5.0M	$-4.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$0	$0	$0	$1.0M	$6.0M
Free Cash Flow	$0	$0	$-4.0M	$-5.0M	$-4.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-12.94
FCF Yield	-6.06%
Quick Ratio	16.14
Interest Coverage	-867.98
Return 1Y	8.09%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held35.10%

Institutions Held3.28%

Institutions Float Held5.05%

Institutional Holder	Shares	Report Date
Vanguard Capital Management LLC	995,373	2026-03-31
Blackrock Inc.	289,198	2026-03-31
Geode Capital Management, LLC	249,086	2026-03-31
Vanguard Fiduciary Trust Co	135,541	2026-03-31
Millennium Management Llc	129,060	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BRNSBarinthus Biotherapeutics plc	$0.67	+4.69%	-0.41	—	0.00%
COEPCoeptis Therapeutics Holdings, Inc.	$10.99	-8.57%	-4.45	$38.62M	0.00%
CVMCel-Sci Corporation	$1.94	-0.51%	-0.90	$13.33M	0.00%
EQEquillium, Inc.	$1.41	-2.08%	-5.50	$89.15M	0.00%
GNTAGenenta Science S.p.A.	$1.50	-5.66%	-3.98	$28.72M	0.00%

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is led by CEO Erez Aminov, employs 1 people, headquartered in US, publicly traded since 2019.

Telomir Pharmaceuticals, Inc. (TELO) stock trades at $1.12 with a market capitalization of $77.03M. The stock is valued at a price-to-earnings (P/E) ratio of -0.78, price-to-book of 8.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.89 and $2.09, and currently trades 46.4% below its 52-week high.

On profitability, Telomir Pharmaceuticals, Inc. generates a return on equity (ROE) of -102.69%, return on capital employed of -120.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides